Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

FrontPoint Partners to Close Funds After Redemption Requests

May 20 (Bloomberg) -- FrontPoint Partners LLC will close some of its hedge funds after clients asked to withdraw money amid charges a manager benefited from an illegal stock tip.

“We have received capital redemption requests from some of our clients,” Steve Bruce, a spokesman for Greenwich, Connecticut-based FrontPoint said in a statement today. The firm “will be winding down select strategies.”

FrontPoint oversaw $7 billion at the start of November before Chip Skowron, a co-portfolio manager of its health-care funds, was tied to claims by prosecutors that the firm got advance notice on drug-trial results. U.S. officials are pursuing a crackdown on insider-trading at hedge funds, with more than 40 people pleading guilty or facing criminal charges or civil lawsuits for benefiting from non-public information.

FrontPoint’s assets had slipped to $4.5 billion by January and the firm closed its health-care funds. The New York Times reported earlier today that FrontPoint planned to shut most of its hedge funds by the end of May.

FrontPoint will honor requests by investors to pull money, Bruce said in the statement. The firm plans to maintain its “core” hedge funds, he said.

“While smaller as a result of these client requests, FrontPoint’s business will continue,” he said.

Charged Last Month

Prosecutors charged Skowron with fraud last month. He was accused of avoiding more than $30 million of trading losses after a French doctor serving as a consultant to Rockville, Maryland-based Human Genome Sciences Inc. passed on that a hepatitis treatment had adverse affects during trials.

Skowron will plead not guilty, his lawyer, James Benjamin Jr., said in an April 14 statement. Yves Benhamou, the French doctor who is alleged to have tipped Skowron to inside information, pleaded guilty on April 11 and is cooperating with U.S. prosecutors.

New York-based Morgan Stanley, owner of the world’s largest brokerage, bought FrontPoint in 2006 for $400 million as part of a push into alternative assets. FrontPoint managers in March bought back a majority stake in the firm.

FrontPoint hedge-fund managers include Steven Eisman, who was profiled by author Michael Lewis in “The Big Short: Inside the Doomsday Machine.” The book, published last year, highlighted investors who made money betting against the U.S. housing market when the real-estate bubble burst in 2007.

Eisman, 48, issued a statement in January that said he was considering adopting a new “structure” that would give him more control over his own business. He also pledged to manage money for FrontPoint and its clients “for many years to come.”

FrontPoint funds overseen by Eisman saw assets decline to $750 million in January from more than $1 billion in 2010.

To contact the reporter responsible for this story: Jesse Westbrook in London at

To contact the editor responsible for this story: Edward Evans at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.